GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a multicenter, randomized, open-label, controlled Phase 2 study in patients with unresectable hepatocellular carcinoma (uHCC). The purpose of this study is to compare the efficacy and safety of GKL-006 Injection in combination with transarterial chemoembolization (TACE) versus TACE alone.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 80 lat
- •Potwierdzony rak wątroby, którego nie można operacyjnie usunąć
- •Co najmniej jeden widoczny na badaniach guz
- •Dobra funkcja wątroby (klasa Child-Pugh A lub B)
- •Dobne wyniki badań krwi i funkcji narządów
- •Dobry stan ogólny (ECOG 0-2)
- •Dobrowolna zgoda na udział w badaniu
✗ Disqualifies
- •Alergia na lek badawczy, albuminy lub IL-2
- •Inny nieuleczalny nowotwór w ciągu ostatnich 5 lat
- •Leczenie guza w ciągu ostatnich 12 tygodni
- •Encefalopatia wątrobowa w ciągu ostatnich 4 tygodni
- •Zbiorniki płynu w brzuchu lub płucach wymagające drażenia
- •Inne aktywne choroby zagrażające zdrowiu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- August 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
302 Hospital
Beijing, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
The Second Xiangya Hospital of Central South University
Changsha, China
Zhongda Hospital
Nanjing, China
Nanjing Second Hospital
Nanjing, China
Jiangxi Cancer Hospital
Nanchang, China
Zhejiang Cancer Hospital
Hangzhou, China
Trial contact
Zhongda Hospital
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.